1021735-42-1

Basic information

• Product Name: Benzenepropanoic acid, 4-bromo-β-methyl-, methyl ester
• Synonyms: Benzenepropanoic acid, 4-bromo-β-methyl-, methyl ester;methyl(S)-3-(4-bromophenyl)butanoate
• CAS NO: 1021735-42-1
• Molecular Formula: C11H13BrO2
• Molecular Weight: 257.127
• Mol File: 1021735-42-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzenepropanoic acid, 4-bromo-β-methyl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenepropanoic acid, 4-bromo-β-methyl-, methyl ester(1021735-42-1)
• EPA Substance Registry System: Benzenepropanoic acid, 4-bromo-β-methyl-, methyl ester(1021735-42-1)

Safety Data

• Hazardous Substances Data: 1021735-42-1(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 2077-19-2 2-(4-bromophenyl)propan-2-ol 
• 3650-78-0 methyl (E)-4-bromocinnamate 
• 676-58-4 methylmagnesium chloride 
• 917-54-4 methyllithium 

Downstream Products

• 1420837-06-4 methyl 3-(4-(phenylethynyl)phenyl)butanoate 
• 20005-55-4 3-(4-bromophenyl)-1-butanol 

Relevant articles and documents

Palladium-Catalyzed Carbonylation of sec- and tert-Alcohols

A general palladium-catalyzed synthesis of linear esters directly from sec- and tert-alcohols is described. Compared to the classic Koch–Haaf reaction, which leads to branched products, this new transformation gives the corresponding linear esters in high yields and selectivity. Key for this protocol is the use of an advanced palladium catalyst system with L2 (pytbpx) as the ligand. A variety of aliphatic and benzylic alcohols can be directly used and the catalyst efficiency for the benchmark reaction is outstanding (turnover number up to 89 000).

SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS

Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.